U.S. markets open in 7 hours 57 minutes
  • S&P Futures

    4,260.25
    +4.25 (+0.10%)
     
  • Dow Futures

    34,200.00
    +118.00 (+0.35%)
     
  • Nasdaq Futures

    14,359.25
    +5.00 (+0.03%)
     
  • Russell 2000 Futures

    2,333.90
    +2.70 (+0.12%)
     
  • Crude Oil

    73.30
    0.00 (0.00%)
     
  • Gold

    1,776.40
    -0.30 (-0.02%)
     
  • Silver

    26.08
    +0.03 (+0.12%)
     
  • EUR/USD

    1.1942
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    15.97
    -0.35 (-2.14%)
     
  • GBP/USD

    1.3924
    +0.0003 (+0.02%)
     
  • USD/JPY

    110.8200
    -0.0150 (-0.01%)
     
  • BTC-USD

    34,537.64
    +1,797.22 (+5.49%)
     
  • CMC Crypto 200

    830.74
    +44.13 (+5.61%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    29,074.95
    +199.72 (+0.69%)
     

CLASS ACTION UPDATE for SPLK, GDRX and AZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / February 1, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

SPLK Shareholders Click Here: https://www.zlk.com/pslra-1/splunk-inc-loss-submission-form?prid=12575&wire=1
GDRX Shareholders Click Here: https://www.zlk.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=12575&wire=1
AZN Shareholders Click Here: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=12575&wire=1

* ADDITIONAL INFORMATION BELOW *

Splunk Inc. (NASDAQ:SPLK)

SPLK Lawsuit on behalf of: investors who purchased October 21, 2020 - December 2, 2020
Lead Plaintiff Deadline : February 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/splunk-inc-loss-submission-form?prid=12575&wire=1

According to the filed complaint, during the class period, Splunk Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

GoodRx Holdings, Inc (NASDAQ:GDRX)

GDRX Lawsuit on behalf of: investors who purchased September 23, 2020 - November 16, 2020
Lead Plaintiff Deadline : February 16, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=12575&wire=1

According to the filed complaint, during the class period, GoodRx Holdings, Inc made materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.

Astrazeneca Plc (NYSE:AZN)

AZN Lawsuit on behalf of: investors who purchased May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline : March 29, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=12575&wire=1

According to the filed complaint, during the class period, Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/627004/CLASS-ACTION-UPDATE-for-SPLK-GDRX-and-AZN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders